Mycobacterium leprae Is Naturally Resistant to PA-824-Reference-Cited by-同舟云学术

Mycobacterium leprae Is Naturally Resistant to PA-824

Published:2006-10 Issue:10 Volume:50 Page:3350-3354
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Manjunatha Ujjini H.¹,Lahiri Ramanuj²,Randhawa Baljit²,Dowd Cynthia S.¹,Krahenbuhl James L.²,Barry Clifton E.¹

Affiliation:

1. Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, 12441 Parklawn Drive, Twinbrook II, Rockville, Maryland

2. Laboratory Research Branch, National Hansen's Disease Programs, Louisiana State University, Skip Bertman Drive, Baton Rouge, Louisiana 70803

Abstract

ABSTRACT Leprosy responds very slowly to the current multidrug therapy, and hence there is a need for novel drugs with potent bactericidal activity. PA-824 is a 4-nitroimidazo-oxazine that is currently undergoing phase I clinical trials for the treatment of tuberculosis. The activity of PA-824 against Mycobacterium leprae was tested and compared with that of rifampin in axenic cultures, macrophages, and two different animal models. Our results conclusively demonstrate that PA-824 has no effect on the viability of M. leprae in all three models, consistent with the lack of the nitroimidazo-oxazine-specific nitroreductase, encoded by Rv3547 in the M. leprae genome, which is essential for activation of this molecule.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00488-06

Reference27 articles.

1. Baker W. R. C. Shaopei and E. L. Keeler. September 1997. Nitroimidazole antibacterial compounds and methods of use thereof. U.S. patent 5 668 127.

2. Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis

3. Camus, J. C., M. J. Pryor, C. Medigue, and S. T. Cole. 2002. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology148:2967-2973.

4. Cellona, R. V., M. F. Balagon, E. C. dela Cruz, J. A. Burgos, R. M. Abalos, G. P. Walsh, R. Topolski, R. H. Gelber, and D. S. Walsh. 2003. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int. J. Lepr. Other Mycobact. Dis.71:308-319.

5. Use of Transposon Tn 5367 Mutagenesis and a Nitroimidazopyran-Based Selection System To Demonstrate a Requirement for fbiA and fbiB in Coenzyme F 420 Biosynthesis by Mycobacterium bovis BCG

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antileprotic drugs;Medicinal Chemistry of Chemotherapeutic Agents;2023

2. Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis;Frontiers in Cellular and Infection Microbiology;2022-08-24

3. Tuberculosis: current scenario, drug targets, and future prospects;Medicinal Chemistry Research;2021-01-20

4. Rodent Models in Leprosy Research;International textbook of leprosy;2020-06-14

5. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid;Antibiotics;2020-03-23